Midazolam

Evidence Level: L2

Predicted Indications: 1

Midazolam

Pharmacist Assessment Report

Midazolam: From Anxiety to Insomnia

One-Sentence Summary

Midazolam is a short-acting benzodiazepine, originally used for anxiety and procedural sedation. The TxGNN model predicts it may be effective for insomnia, with 2 clinical trials (neither a direct insomnia treatment trial) and 10 publications (including 4 RCTs, mostly from 1981–1990) currently related to this direction.

Quick Overview

Item	Content
Original Indication	Anxiety
Predicted New Indication	Insomnia
TxGNN Prediction Score	0.9974
Evidence Level	L2
Canada Market Status	Marketed (marketed DINs: 14 of 14)
Number of DINs	14 (marketed: 14)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for midazolam is not available in the data compiled for this report. Based on known pharmacology, midazolam is a benzodiazepine that positively modulates GABA-A receptors, enhancing inhibitory neurotransmission and producing sedative-hypnotic effects.

Anxiety and insomnia share a state of central nervous system hyperarousal. Benzodiazepine hypnotics such as flurazepam and triazolam are already used for insomnia, so the link between midazolam’s action and the disease is biologically plausible and has clinical precedent.

Oral midazolam was studied as a hypnotic from the early 1980s to 1990. However, that evidence is old. Its short half-life, tolerance, dependence, rebound insomnia, next-day impairment and many drug interactions (largely CYP3A4-mediated) limit its suitability compared with currently preferred insomnia therapies.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02142595	Phase 4	Completed	111	Dexmedetomidine vs midazolam sedation with spinal anaesthesia: postoperative sleep quality after transurethral prostatic resection. Indirect evidence (perioperative setting, not chronic insomnia).
NCT00886314	Not applicable	Unknown	80	Clown doctors vs sedative premedication for pre-operative anxiety in children. Minimal relevance to insomnia.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
2121802	1990	RCT	J Clin Psychopharmacol	Randomised, double-blind multicentre study of sleep, performance and mood in chronic insomniacs during 14-day use of flurazepam vs midazolam
2229461	1990	RCT	J Clin Psychopharmacol	Executive summary of the same multicentre 14-day flurazepam vs midazolam study in chronic insomnia
6138072	1983	RCT	Br J Clin Pharmacol	Midazolam 15 mg vs Vesparax in 30 patients with insomnia secondary to neuromuscular disease. Both were effective hypnotics; midazolam was better tolerated and caused no hangover.
6120704	1981	RCT	Arzneimittel-Forschung	Dose-finding study of oral midazolam 10–30 mg in 75 hospitalised patients with mild to moderate insomnia
2883820	1986	Review	Acta Psychiatr Scand Suppl	Clinical use of hypnotics and the need for a variety of agents; benzodiazepines differ in pharmacokinetic and pharmacodynamic profiles
17988972	2007	Review	Orv Hetil	Review of insomnia and cerebral hypoperfusion (general background)
36615100	2022	Other	J Clin Med	Pilot study of lemborexant for insomnia and delirium prevention after endoscopic procedures under deep sedation (indirect)

Canada Market Information

DIN	Product Name	Dosage Form	Approved Indication
02242905	MIDAZOLAM INJECTION, USP	Not specified	Not specified
02559579	BUCCOLAM	Not specified	Not specified
02498022	MIDAZOLAM INJECTION USP	Not specified	Not specified
02382385	MIDAZOLAM INJECTION USP	Not specified	Not specified
02240286	MIDAZOLAM INJECTION	Not specified	Not specified

Fourteen valid single-ingredient DINs are listed in total; no authorisations are cancelled.

Safety Considerations

Contraindications flagged by the knowledge graph (not taken from label text): chronic obstructive pulmonary disease (including severe early onset), cirrhosis of liver, angle-closure glaucoma, and chronic kidney disease (including chronic renal failure and end stage renal failure).
Drug Interactions: 100 interactions were recorded. Those reviewed include moderate-level interactions with ranitidine, bupropion, aprepitant, morphine, omeprazole, cimetidine, clarithromycin, dronabinol, eluxadoline, teduglutide, nabilone, metoclopramide, miconazole, clotrimazole and glycerol phenylbutyrate. Minor-level interactions include dexamethasone, betamethasone, magnesium oxide, aluminium hydroxide and calcium carbonate. Many are likely CYP3A4-mediated, and combination with opioids or other central nervous system depressants warrants particular caution.
Class-level concerns for hypnotic use: tolerance, dependence, rebound insomnia and next-day impairment.

Please also refer to the package insert for full warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: Midazolam has a biologically plausible mechanism and several older randomised trials in insomnia. However, that evidence dates from 1981–1990, the two registered trials are only indirectly relevant, and the drug’s pharmacological limitations make it a poor fit against current insomnia therapies. The Health Canada indication text and label safety information are also unavailable, so safety screening cannot yet proceed.

To proceed, the following is needed:

Health Canada package insert warnings and contraindications, plus approved indication text for each DIN
Detailed mechanism of action data (for example, from DrugBank)
A comparison with current standard insomnia treatments (efficacy, dependence risk, next-day impairment)
Confirmation of route and formulation compatibility (current Canadian products are injectable and buccal, not an oral hypnotic)
A review of the interaction burden and a monitoring plan for patients with COPD, liver disease, kidney disease or glaucoma
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.